Kit for quantitative detection of braf mutation
OwnerJunpu Xu, Zhao Chen +1inventors
InventorsJunpu Xu, Zhao Chen, Jun Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method and assay kit for BRAF gene mutations which relates to the effect of molecule-targeting anti-tumor drug. Particularly, the present invention relates to a fluorescent quantitative PCR method and kit for detecting mutations at hotspots of BRAF gene, together with the use thereof. The present invention detects the mutations at specific sites of BRAF gene, and can predict the therapeutic efficacy of anti-EGFR tyrosine kinase inhibitors, an anti-tumor drug. Therefore, the present invention can provide a guidance to individualized treatments for cancer patients.
Claims14
An assay kit for quantitatively detecting BRAF gene mutations, comprising:
- (1) a PCR primer which binds nucleotides within a sequence under a suitable PCR condition, said sequence having 200 bases and comprising a mutation site of the BRAF gene;
- (2) a probe for fluorescent quantitative PCR, said probe specifically binding to the base sequence at said mutation site of the BRAF gene under a suitable PCR condition;
- and
- (3) a standard comprising a wild-type plasmid, mutant plasmid, or both a wild-type plasmid and a mutant plasmid, said wild-type plasmid comprising a wild-type BRAF sequence, and said mutant plasmid comprising a mutant BRAF sequence.
A standard, which comprises a wild-type plasmid, a mutant plasmid, or both a wild-type plasmid and a mutant plasmid, said wild-type plasmid comprising a wild-type BRAF sequence, and said mutant plasmid comprising a mutant BRAF sequence.
Dependencies are inferred from the claim text.